Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

Bernadette Biondi,&nbsp;Melania Pulcrano, Loredana Pagano, Gaetano LombardiDepartment of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Naples, ItalyAbstract: Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano Lombardi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/96ab15e2218549b3bdfa6a869b362644
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96ab15e2218549b3bdfa6a869b362644
record_format	dspace
spelling	oai:doaj.org-article:96ab15e2218549b3bdfa6a869b3626442021-12-02T05:38:51ZAdjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer1177-54751177-5491https://doaj.org/article/96ab15e2218549b3bdfa6a869b3626442008-12-01T00:00:00Zhttp://www.dovepress.com/adjuvant-treatment-with-thyrotropin-alpha-for-remnant-ablation-in-thyr-a2652https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Bernadette Biondi,&nbsp;Melania Pulcrano, Loredana Pagano, Gaetano LombardiDepartment of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Naples, ItalyAbstract: Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US Federal Drug Administration approved the use of rhTSH for adjuvant treatment with radioiodine in patients with DTC without evidence of metastatic thyroid cancer. Quality of life was found to be better with rhTSH preparation than with L-thyroxine withdrawal, thereby resulting in benefits for society as a whole. Furthermore, rhTSH for radioiodine remnant ablation results in a longer effective radioiodine half-life within remnant thyroid tissue and a lower specific absorbed dose in the blood and exposure of bone marrow to X-rays. More studies are required to establish the amount of radioiodine to be administered especially in high-risk patients. Keywords: thyroid cancer, thyrotropin, radioiodine (131I) remnant ablation (RRA), quality of life, ray exposure Bernadette BiondiMelania PulcranoLoredana PaganoGaetano LombardiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 9-13 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bernadette Biondi Melania Pulcrano Loredana Pagano Gaetano Lombardi Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
description	Bernadette Biondi,&nbsp;Melania Pulcrano, Loredana Pagano, Gaetano LombardiDepartment of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Naples, ItalyAbstract: Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US Federal Drug Administration approved the use of rhTSH for adjuvant treatment with radioiodine in patients with DTC without evidence of metastatic thyroid cancer. Quality of life was found to be better with rhTSH preparation than with L-thyroxine withdrawal, thereby resulting in benefits for society as a whole. Furthermore, rhTSH for radioiodine remnant ablation results in a longer effective radioiodine half-life within remnant thyroid tissue and a lower specific absorbed dose in the blood and exposure of bone marrow to X-rays. More studies are required to establish the amount of radioiodine to be administered especially in high-risk patients. Keywords: thyroid cancer, thyrotropin, radioiodine (131I) remnant ablation (RRA), quality of life, ray exposure
format	article
author	Bernadette Biondi Melania Pulcrano Loredana Pagano Gaetano Lombardi
author_facet	Bernadette Biondi Melania Pulcrano Loredana Pagano Gaetano Lombardi
author_sort	Bernadette Biondi
title	Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
title_short	Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
title_full	Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
title_fullStr	Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
title_full_unstemmed	Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
title_sort	adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/96ab15e2218549b3bdfa6a869b362644
work_keys_str_mv	AT bernadettebiondi adjuvanttreatmentwiththyrotropinalphaforremnantablationinthyroidcancer AT melaniapulcrano adjuvanttreatmentwiththyrotropinalphaforremnantablationinthyroidcancer AT loredanapagano adjuvanttreatmentwiththyrotropinalphaforremnantablationinthyroidcancer AT gaetanolombardi adjuvanttreatmentwiththyrotropinalphaforremnantablationinthyroidcancer
_version_	1718400311143432192

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer

Ejemplares similares